Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Seagen Inc.
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
National Cancer Institute (NCI)
Shanghai Jiao Tong University School of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)